1.	Phase III Study of IL-2 vs IL-2 plus PEG-IL-2 in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 07/97) Phase: Phase III Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-90-C-85C, NCI-T90-0053N, T90-0053
2.	Phase I/II Study of Intratumoral PEG-IL-2 in Patients with Clinical Stage B2/C Prostate Cancer Undergoing Radical Prostatectomy (Summary Last Modified 07/97) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UCLA-HSPC-9402069, NCI-V94-0537
3.	Phase II Multicenter Evaluation of Adjuvant Recombinant PEG Human Interleukin-2 Given as a Weekly Bolus to Adult Patients with AML in Remission After First Relapse (Summary Last Modified 05/91) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: AECM-9002042, NCI-V90-0035
4.	Phase II Study of PEG-IL-2 in Patients with Advanced Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: UNM-0989C, NCI-V89-0215
5.	Phase I Study of Polyethylene Glycol-Modified Recombinant Human Interleukin-2 in Patients with Metastatic Cancer (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-89-C-131B, NCI-T89-0085N, T89-0085
6.	Phase I Study of PEG-IL-2 in Patients with Cytogenetic or Clinical Relapse of CML Following Allogeneic Marrow Transplantation (Summary Last Modified 08/90) Phase: Phase I Type: Treatment Status: Completed Age: 18 to physiologic 70 Sponsor: Protocol IDs: MSKCC-90022, NCI-V90-0072